JENNIFER GRAY: Open Payments
NPI 1083962849 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,465 in 87 payments from 8 companies in 2025. Trend: 2023 $1,569 · 2024 $1,543 · 2025 $1,465
Food & beverage: $1,465
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $411 |
| Alkermes, Inc. | 17 | $299 |
| Teva Pharmaceuticals USA, Inc. | 33 | $275 |
| E.R. Squibb & Sons, L.L.C. | 10 | $218 |
| Vanda Pharmaceuticals Inc. | 5 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
Products named: INGREZZA, ARISTADA, AUSTEDO XR, COBENFY, FANAPT, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across GA — which companies pay providers there.
